

Remarks

The specification has been amended to remove embedded hyperlinks, as requested by the Examiner. This amendment should obviate the objection to the specification. No new matter has been introduced by this amendment. A "marked-up" version of the replacement paragraph, as required under 37 C.F.R. 1.121(b)(1)(iii), is included herein as Appendix A.

Claims 1-4, 9-12 and 23-33 are pending in the application. Claims 23-29 and 31-33 have been cancelled without prejudice, to the filing of a continuation application. Claim 30 has been rewritten in independent form, with all the limitations of the base claim and any intervening claims and should now be allowable. A "marked up" version of the amended claim has been included herein as Appendix B, as required by 37 C.F.R. 1.121(c)(1)(ii).

Response to the Section 112, 1st paragraph rejection


Claims 23-29 and 31-33 are rejected under 35 U.S.C. 112, 1st paragraph as allegedly non-enabled. In the interests of furthering prosecution, Applicants have cancelled these claims without prejudice, to the filing of a continuation application. The cancellation of claims 23-29 and 31-33 should not be construed as an acquiescence on the part of the Applicants to the Examiner's position regarding these claims.

Conclusion

Based on the foregoing, Applicants believe that all pending claims are in condition for allowance. An early and favorable action in this regard is earnestly solicited.

Respectfully submitted,

JAY S. SCHNEIDER

BY 
DANIEL A. MONACO
Registration No. 30,480
DRINKER, BIDDLE & REATH, LLP.
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103
(215) 988-3312 ph.
(215) 988-2757 fax
Attorney for Applicant

Appendix A – “Marked-up” Version of Amended Replacement Paragraph as Required Under 37 C.F.R. 1.121(b)(1)(iii)

Paragraph on at pg. 8, ln. 27 to pg. 9, ln. 3:

These sequences were obtained by searching Genbank for the appropriate gene name. These sequences were analyzed using an open reading frame finder program at the National Center for Biotechnology Information World Wide Web site [<http://www.ncbi.nlm.nih.gov/cgi-bin/gorf/orfig>]. The initiation of translation site was found and a 21 base antisense molecule complementary to the region spanning 8 bases 5' to 13 bases 3' (-8 to +13) to the initiation triplet was selected. These 21 base oligonucleotides were analyzed for cross reactivity with other genes using the NCBI BLAST server [<http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST/>].

Appendix B – “Marked-up” Version of Amended Claims as Required Under 37 C.F.R. 1.121(c)(1)(ii)

30. (once amended) [The method of Claim 29] A method of downregulating glutamic acid decarboxylase in a mammal *in vivo* comprising administering an antisense oligonucleotide directed to an initiation codon of glutamic acid decarboxylase mRNA to the substantia nigra pars reticulata or internal globus pallidus via a cannula, wherein said antisense oligonucleotide comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.